Scholars Central

Conference abstractPublished 10 May 2018

Endocrine treatment of breast cancer: current concepts to predict and prevent relapse

Authors: Hiltrud Brauch

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Germany

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Standard-of-care in endocrine treatment is the blockade of estrogen signaling via long-term estrogen deprivation. Tamoxifen, a selective ER modulator blocks 17Ã?Â?-estradiol binding to stop tumor growth, and aromatase inhibitors (AI) block the aromatase enzyme to prevent conversion of androgens to estrogens. Despite their effectiveness one third of the patients develop recurrences leading to disease progression and death. Tamoxifen failure is attributed to a lack of bioactivation towards its active metabolite endoxifen that is mainly mediated by the polymorphic CYP2D6 enzyme for which distinct genetically determined functional variants are present in the general population. Inter-individual differences in CYP2D6 enzyme activities are grouped into the phenotypes ultra-rapid (UM), extensive (EM), intermediate (IM) and poor (PM) metabolizers. EM patients have high levels of endoxifen and are likely to benefit whereas PM patients have low endoxifen levels and a significant risk to relapse. Therefore, CYP2D6 polymorphism and plasma endoxifen levels may serve as tamoxifen outcome predictors; however findings from others do not support this view. I will discuss the controversy and suggest a way forward towards solutions to better serve the patientsâÂ?Â? needs. With regards to AI treatment, it is well known that long-term estrogen deprivation leads to the reconfiguration of survival signaling in that such reconfigured tumor cells eventually become sensitive towards estrogen, a mechanism known as E2-inducible apoptosis. While this potential further treatment option is being explored in clinical trials, I will show that distinct microRNA patterns characterize AI resistance and discuss their potential as biomarkers to identify patients at risk for relapse and those susceptible to E2-inducible apoptosis towards the prevention of relapse

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Hiltrud Brauch”